New eLearning course on Metallo-β-Lactamase Infections

MBL-producing pathogens are emerging as a global public health threat. The British Society for Antimicrobial Chemotherapy (BSAC) continues to support the educational needs of healthcare professionals by promoting early diagnosis of MBL-producing bacterial infections and enhancing patient management through the development of this valuable resource.

Next-Generation Sequencing (NGS) Joins Bruker’s Microbiology & Infection Diagnostics Toolbox We’re expanding our portfolio with Ridom’s software solution for processing and analyzing of NGS data! NGS is transforming the way we understand microbial genomics. With its ability to deliver high-resolution insights into pathogen transmission, resistance mechanisms, and outbreak dynamics, NGS is becoming an essential tool in 𝗲𝗽𝗶𝗱𝗲𝗺𝗶𝗼𝗹𝗼𝗴𝘆 and 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹-𝗮𝗰𝗾𝘂𝗶𝗿𝗲𝗱 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 (𝗛𝗔𝗜) 𝘁𝗿𝗮𝗰𝗶𝗻𝗴. The solution is designed to empower microbiologists, infection control teams, and public health researchers with intuitive, automated workflows - making complex genomic data more accessible than ever. This expansion reflects our commitment to innovation and to supporting the global scientific community in tackling infectious diseases with precision and speed. Stay tuned - we’ll be sharing more details soon!

How we tested vaccine-driven evolution in PRRSV-2 (Methods explainer) We used controlled sequential infections, serial sampling, and whole-genome sequencing to observe how PRRSV-2 changes under different immune conditions. This design lets us see lower viral burden with vaccination and adaptive changes under immune pressure—a reminder to keep vaccinating + add targeted genomic surveillance. #PEDIL #PRRSV #Swinehealth #Epidemiology 📄 Paper: https://lnkd.in/gkMBH2ti

This is a MUST-read for anyone conducting healthcare research! Dr. JAM breaks down the use, application, and limitations of area-deprivation indices. Their use in healthcare-associated infections is thought-provoking, with broad applications across different clinical specialties. Well done, as always, friend!

A recent study demonstrates that a model-predictive control approach can optimize the timing of non-pharmaceutical interventions during infectious disease outbreaks, even when real-time case data is noisy or incomplete. Simulations using COVID-19 and Ebola-like scenarios showed that this method generally achieves better epidemic control and reduces intervention costs compared to preset schedules or simple thresholds. The findings highlight the importance of adaptive, data-driven decision-making and underscore the value of timely, accurate surveillance to inform public health responses and minimize outbreak impact.

Parainfluenza Virus Infection Market: Insights on Epidemiology, Treatments, and Key Companies | Ansun Biopharma, AlloVir: Parainfluenza Virus Infection Market The Parainfluenza Virus Infection Market is projected to witness consistent growth throughout the forecast period (2024–2034). The Parainfluenza Virus Infection Market Size in the 7MM is expected to increase, driven by increasing Incident population.   Emerging … Continue reading → #Europe #HealthMedicine #PharmaceuticalsBiotech #UK #US

🔍 Understanding Colonization Pressure and Hospital-Acquired Infections Hospital-acquired infections (HAIs) remain a persistent challenge in healthcare systems worldwide. Active surveillance for bacterial colonization is effective—but also resource-intensive and often limited to high-risk units. A new retrospective study spanning nearly a decade (2015–2024) across a large regional healthcare system explores an innovative alternative: using colonization pressure (CP)—the prevalence of pathogens among ward co-occupants—as a real-time, system-wide predictor of nosocomial infection risk. 📊 Key insights from the study: Over 14,900 cases were matched to 28,480 controls. Hospital acquisition was 4x more common for drug-susceptible organisms than drug-resistant ones. Strong positive associations were observed between: CP for C. difficile and acquisition of C. difficile (+32.5%) CP for ESBL-producing K. pneumoniae and its acquisition (+29.4%) CP for drug-resistant P. aeruginosa and its acquisition (+28.6%) Interestingly, negative associations emerged between organisms from different ecological niches—hinting at possible microbial competition. ❗ A patient’s likelihood of acquiring a pathogen in the hospital is closely tied to how prevalent that organism is among nearby patients—independent of drug resistance. This suggests that passive, data-driven surveillance using EHR-derived CP could enhance infection prevention strategies beyond traditional, resource-heavy screening. https://lnkd.in/dtMt7AX2 #InfectionPrevention #HospitalEpidemiology #PatientSafety #HealthcareInnovation #DigitalHealth #HealthDataScience #ClinicalInformatics #EHR #AntimicrobialResistance

Are there CLSI SUSCEPTIBLE breakpoints for Daptomycin for Enterococcus faecium? 🤔 There is a Clinical and Laboratory Standards Institute (CLSI) defined susceptible range for daptomycin when testing Enterococcus faecium, but it is classified as "susceptible dose-dependent (SDD)" rather than simply "susceptible". The CLSI SDD breakpoint for E. faecium is ≤4 μg/mL, which is based on the expectation that higher daptomycin doses (8–12 mg/kg/day) will be used for isolates in this range. Isolates with MICs ≥8 μg/mL are considered resistant -- > The SDD category reflects the need for increased dosing and infectious diseases consultation for optimal use.[1-3] For other enterococcal species, CLSI defines ≤2 μg/mL as susceptible, 4 μg/mL as intermediate, and ≥8 μg/mL as resistant, based on standard dosing (6 mg/kg/day).[1] The American Heart Association also recognizes the SDD breakpoint and recommends high-dose daptomycin (8–12 mg/kg/day) for E. faecium infections, especially those with MICs at the upper end of the SDD range.[4] In summary, the CLSI susceptible range for daptomycin in Enterococcus faecium is ≤4 μg/mL, but only in the context of high-dose therapy (SDD category).[1-3] My take: - Today I asked pharmacy to dose Dapto @10 mg/kg for E.faecium (a severe SSTI - polymicrobial -) and I got the call 10' minutes later = PHARMACIST = " Dr Gnoni, its INTERMEDIATE, is it ok to dose?" ME = yeah, I know, that's why I went BIG on the dose..." and please don't forget to HOLD STATINS and TREND THE CK levels... also...if you see Eosinophilia coming up too quickly page me 😎 , he is at risk of EOSINOPHILIC PNEUMONIA (but likely not with short term use) 1. Development of Daptomycin Susceptibility Breakpoints for Enterococcus Faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.Satlin MJ, Nicolau DP, Humphries RM, et al.Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2020;70(6):1240-1246. doi:10.1093/cid/ciz845.  Leading Journal 2.Daptomycin Susceptibility Testing and Therapeutic Use in Enterococcal Bloodstream Infection (EBSI) in a Setting With High Rates of Vancomycin-Resistant Enterococcus Faecium (VREfm).Kelly J, Tysall L, Dewar S. The Journal of Antimicrobial Chemotherapy. 2022;77(5):1432-1435. doi:10.1093/jac/dkac042. 3.Influence of Daptomycin Doses on the Outcomes of VRE Bloodstream Infection Treated With High-Dose Daptomycin.Chuang YC, Lin HY, Yang JL, et al.The Journal of Antimicrobial Chemotherapy. 2022;77(8):2278-2287. doi:10.1093/jac/dkac164. 4.Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.Baddour LM, Wilson WR, Bayer AS, et al.Circulation. 2015;132(15):1435-86. doi:10.1161/CIR.0000000000000296.

Catheter-Related Bloodstream Infections Market: Epidemiology, Treatments, and Key Players | DelveInsight: Catheter-Related Bloodstream Infections Market The Catheter Related Bloodstream Infection Drugs Market Report also covers current catheter-related bloodstream infection treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.   Key companies in … Continue reading → #Europe #HealthMedicine #PharmaceuticalsBiotech #UK #US